Compare CKX & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CKX | DARE |
|---|---|---|
| Founded | 1930 | 2015 |
| Country | United States | United States |
| Employees | 2 | 23 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.1M | 21.0M |
| IPO Year | 1996 | 2014 |
| Metric | CKX | DARE |
|---|---|---|
| Price | $10.75 | $1.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 1.5K | ★ 61.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.43 | N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | $1,521,124.00 | ★ $2,807,885.00 |
| Revenue This Year | N/A | $3,843.33 |
| Revenue Next Year | N/A | $8,700.33 |
| P/E Ratio | $48.86 | ★ N/A |
| Revenue Growth | ★ 2.39 | N/A |
| 52 Week Low | $8.66 | $1.42 |
| 52 Week High | $13.25 | $9.19 |
| Indicator | CKX | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 50.50 | 33.13 |
| Support Level | $10.25 | N/A |
| Resistance Level | $11.20 | $1.74 |
| Average True Range (ATR) | 0.56 | 0.06 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 15.73 | 18.75 |
CKX Lands Inc is a Louisiana corporation organized to receive non-producing mineral royalties spun off by a southwest Louisiana bank. It operates in three segments: Oil and Gas, Surface, and Timber. The company owns land and mineral interests and collects income through its ownership of oil and gas royalties, surface leases for farming, the right of way and other uses, and timber sales. The company's oil and gas royalties are paid by the operators who own the wells, and timber income is paid by the highest bidder for the timber. CKX has small royalty interests in approximately 20 different producing oil and gas fields. Maximum revenue for the company is generated from the Surface segment. Geographically, it generates all of its revenue from the United States of America.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.